BioCentury
ARTICLE | Company News

Clarient, Indiana Research and Technology Corp. (IURTC) deal

April 27, 2009 7:00 AM UTC

Clarient received exclusive, worldwide rights to commercialize IURTC's IP covering the forkhead box A1 (FOXA1) biomarker, which predicts the likelihood of recurrence and long-term, disease-free breas...